Company Percheron Therapeutics Limited OTC Markets
Equities
ATHJF
AU0000317281
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.012 USD | -84.00% |
|
-.--% | +20.00% |
06-17 | Percheron Therapeutics Appoints CFO | MT |
06-03 | Percheron Therapeutics Names Chief Medical Advisor | MT |
Business Summary
Number of employees: 8
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
ATL 1102
80.4
%
| 2 | 98.1 % | 2 | 80.4 % | -11.14% |
Unallocated
19.6
%
| 0 | 1.9 % | 0 | 19.6 % | +1,026.23% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia
100.0
%
| 2 | 100.0 % | 2 | 100.0 % | +8.43% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
James Garner
CEO | Chief Executive Officer | - | 07/05/23 |
Anthony Filippis
COO | Chief Operating Officer | - | 31/10/22 |
Andrew McKenzie
PRN | Corporate Officer/Principal | - | - |
Alicia Mellors
SEC | Corporate Secretary | - | 23/02/21 |
George Tachas
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Ben Price
BRD | Director/Board Member | 68 | 03/10/21 |
James Garner
CEO | Chief Executive Officer | - | 07/05/23 |
Chairman | - | 21/03/21 |
Company contact information
Percheron Therapeutics Ltd.
Collins Place 35 Collins Street
3000, Melbourne
+61 3 9827 8999
http://www.PercheronTx.com![address Percheron Therapeutics Limited(ATHJF)](https://cdn.zonebourse.com/static/address/120790729.png)
Sector
Sales per Business
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+15.21% | 122B | |
+15.74% | 113B | |
+17.55% | 26.22B | |
-23.94% | 19.01B | |
-19.14% | 15.71B | |
-17.77% | 15.22B | |
-46.81% | 14.72B | |
+57.37% | 14.58B | |
+4.96% | 13.84B |
- Stock Market
- Equities
- PER Stock
- ATHJF Stock
- Company Percheron Therapeutics Limited